ArticleNature communications2020
Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- The anion channel GPR89 is a tumor-specific dependency in breast cancer.Nature communications · 2026Article
- The Current Landscape of Metastatic Breast Cancer: A Pathology Guide on Emerging Biomarkers.Cancers · 2026Review
- Exploration of the clonal evolution and construction of the tumor clonal evolution rate as a prognostic indicator in metastatic breast cancer.BMC medicine · 2025Article
- Exploring evolutionary trajectories in ovarian cancer patients by longitudinal analysis of ctDNA.Clinical chemistry and laboratory medicine · 2024Article
- Estrogen-Receptor Loss andCancers · 2024Article
- Research autopsy programmes in oncology: shared experience from 14 centres across the world.The Journal of pathology · 2024Article
- Global post-mortem tissue donation programmes to accelerate cancer research.Nature reviews. Cancer · 2024Article
- Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data.Journal of cancer research and clinical oncology · 2023Review
- Article
- Article
- Future perspectives of uveal melanoma blood based biomarkers.British journal of cancer · 2022Review
- Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Current and Future Clinical Applications of ctDNA in Immuno-Oncology.Cancer research · 2022Review
- Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise.Diagnostics (Basel, Switzerland) · 2022Review
- Liquid biopsy for children with central nervous system tumours: Clinical integration and technical considerations.Frontiers in pediatrics · 2022Review
- Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study.Nature ecology & evolution · 2022Article
- Subclonal heterogeneity and evolution in breast cancer.NPJ breast cancer · 2021Review
- Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses.Nature communications · 2021Article
- DeCiFering the elusive cancer cell fraction in tumor heterogeneity and evolution.Cell systems · 2021Article
- MSIsensor-ct: microsatellite instability detection using cfDNA sequencing data.Briefings in bioinformatics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
Abstract
Circulating tumour DNA (ctDNA) allows tracking of the evolution of human cancers at high resolution, overcoming many limitations of tissue biopsies. However, exploiting ctDNA to determine how a patient's cancer is evolving in order to aid clinical decisions remains difficult. This is because ctDNA is a mix of fragmented alleles, and the contribution of different cancer deposits to ctDNA is largely unknown. Profiling ctDNA almost invariably requires prior knowledge of what genomic alterations to track. Here, we leverage on a rapid autopsy programme to demonstrate that unbiased genomic characterisation of several metastatic sites and concomitant ctDNA profiling at whole-genome resolution reveals the extent to which ctDNA is representative of widespread disease. We also present a methylation profiling method that allows tracking evolutionary changes in ctDNA at single-molecule resolution without prior knowledge. These results have critical implications for the use of liquid biopsies to monitor cancer evolution in humans and guide treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.